- This document has been redacted by Sam Collaudin, Kinexum Business Strategy Consultant, independently from any pharmaceutical and biotech companies
- It synthesizes selected data presented during the ATTD 2021 conference
- Grey rectangles are personal comments and opinions, underlined words are clickable links to other slides or external references
- If you have comments, please contact me by email (samcollaudin@kinexum.com)
- Disclosure: Business strategy consultant at Modular Medical, CEO of Abvance Kinexum , consultant for Therapeutics, chairman of a non for profit French health care insurance company (Groupe Operating Since 2003 Uitsem)
{iframe}https://documentcloud.adobe.com/link/track?uri=urn%3Aaaid%3Ascds%3AUS%3Ad2760538-9909-4f1c-9fbf-533507301b5d#pageNum=1{/iframe}